Financial Performance - Corteva reported a strong year in 2025, with fourth-quarter results aligning with expectations, except for stronger cash flow generation than anticipated. The company achieved low single-digit top-line growth and low double-digit operating EBITDA growth, resulting in over 200 basis points of margin expansion, surpassing 22% for the first time as a public company [7][19]. - For the fourth quarter, organic sales decreased by 4% year-over-year, with crop protection experiencing volume and price declines of 2% and 1%, respectively. Seed pricing increased by 3%, but volume declined by 8% due to timing shifts [15][16]. Business Line Performance - The seed business showed organic growth across all regions, with significant net cost improvements of approximately $340 million and $90 million in royalty improvements, particularly in North America corn and soybean licensing in Brazil. The company anticipates crossing double-digit trait penetration for Conkesta in Brazil [8][12]. - The crop protection business also performed well, achieving top and bottom line growth despite challenging market conditions. The business generated over $300 million in productivity and cost benefits, with a strong pipeline of differentiated technologies valued at $9 billion [9][10]. Market Insights - The agricultural fundamentals remain mixed, with record demand for food and fuel, while major crop inventories are within normal ranges despite large crops in Brazil and North America. Farmers are prioritizing top-tier seed technologies while managing tighter margins [10][11]. - The company expects modest growth in the crop protection market for 2026, with competitive pricing dynamics persisting in major markets, including Latin America and Asia-Pacific [10][11]. Strategic Direction - Corteva is on track for a separation in the second half of 2026, with ongoing preparations for executive leadership teams and capital structure submissions. The company aims to sharpen focus, accelerate innovation, and unlock value through this transition [4][5][14]. - A recent agreement with Bayer regarding seed freedom to operate is expected to enhance licensing opportunities and provide business certainty, allowing for accelerated introduction of proprietary technologies [11][12]. Management Commentary - Management expressed confidence in the 2026 outlook, reiterating a preliminary operating EBITDA midpoint of $4.1 billion, reflecting a 7% growth compared to the prior year. The guidance includes momentum in seed licensing, growth in crop protection volumes, and productivity benefits [10][20]. - The company highlighted the importance of gene editing technology and its potential impact on profitability for farmers, with expectations for regulatory approvals in Europe and China [48][49]. Other Important Information - Free cash flow improved significantly to $2.9 billion, driven by increased EBITDA and working capital discipline. The company plans to return approximately $500 million to shareholders through share repurchases in the first half of 2026 [19][21]. - The company anticipates a currency tailwind in 2026, primarily from the Brazilian real, euro, and Canadian dollar, which is expected to positively impact net sales and operating EBITDA [23]. Q&A Session Summary Question: Can you break down the Bayer litigation and its impact on licensing? - Management expressed satisfaction with the agreement, highlighting increased access to the licensing market and freedom to operate, which accelerates corn licensing to 2027 and opens opportunities in cotton [30][31]. Question: What is the impact of the Bayer agreement on existing licensing expenses? - The company confirmed a net royalty benefit of $120 million in 2026, with some Bayer royalties no longer applicable, leading to a net-neutral position two years ahead of expectations [36][40]. Question: How do you view the U.S. order books for the upcoming year? - Management reported strong order books, with prepay collections on par with the prior year, indicating a positive start to the year despite potential shifts in corn and soybean acreage [51][52]. Question: What are the expectations for free cash flow in 2026? - The company anticipates a slight decrease in free cash flow as working capital normalizes, but overall performance is expected to align with long-term targets [55][57]. Question: Can you provide updates on Conkesta soybeans in Brazil? - Management expects to double market share in 2026, with significant contributions to earnings from the Conkesta transition [63][76].